Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free NLTX Stock Alerts

Neoleukin Therapeutics (NLTX) Competitors

Neoleukin Therapeutics logo
$26.85 +0.76 (+2.91%)
As of 05/1/2026
Compare

NLTX vs. AKTS, ALVO, SVRA, CRON, and AMPH

Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Aktis Oncology (AKTS), Alvotech (ALVO), Savara (SVRA), Cronos Group (CRON), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aktis OncologyN/A N/A N/A
Neoleukin Therapeutics N/A -37.22%-30.91%

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aktis Oncology has higher revenue and earnings than Neoleukin Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aktis Oncology$6.50M156.14N/AN/AN/A
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Aktis Oncology presently has a consensus price target of $32.00, suggesting a potential upside of 68.37%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Aktis Oncology had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 8 mentions for Aktis Oncology and 1 mentions for Neoleukin Therapeutics. Aktis Oncology's average media sentiment score of 0.17 beat Neoleukin Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aktis Oncology
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Aktis Oncology beats Neoleukin Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Alvotech?

Neoleukin Therapeutics (NASDAQ:NLTX) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Alvotech had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Alvotech and 1 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Alvotech has a consensus price target of $7.60, suggesting a potential upside of 116.22%. Given Alvotech's stronger consensus rating and higher possible upside, analysts clearly believe Alvotech is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alvotech
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alvotech has a net margin of 4.74% compared to Neoleukin Therapeutics' net margin of 0.00%. Alvotech's return on equity of -11.92% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neoleukin TherapeuticsN/A -37.22% -30.91%
Alvotech 4.74%-11.92%2.02%

Alvotech has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A
Alvotech$588.90M1.80$27.92M$0.1035.15

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alvotech beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Savara?

Neoleukin Therapeutics (NASDAQ:NLTX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Neoleukin Therapeutics and Neoleukin Therapeutics both had 1 articles in the media. Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Savara'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Savara
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Savara has a consensus price target of $9.13, suggesting a potential upside of 78.05%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Savara
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Neoleukin Therapeutics' return on equity of -37.22% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
Neoleukin TherapeuticsN/A -37.22% -30.91%
Savara N/A -84.01%-63.60%

Savara is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A
SavaraN/AN/A-$118.84M-$0.53N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Savara beats Neoleukin Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Cronos Group currently has a consensus price target of $2.30, suggesting a potential downside of 12.71%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cronos Group has higher revenue and earnings than Neoleukin Therapeutics. Cronos Group is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$146.59M6.76-$9.45M-$0.01N/A
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Neoleukin Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -6.44%. Cronos Group's return on equity of -1.12% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group-6.44% -1.12% -1.07%
Neoleukin Therapeutics N/A -37.22%-30.91%

Cronos Group has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

In the previous week, Cronos Group had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 1 mentions for Neoleukin Therapeutics. Cronos Group's average media sentiment score of 0.84 beat Neoleukin Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cronos Group beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 1 mentions for Neoleukin Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.54 beat Neoleukin Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amphastar Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Amphastar Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Amphastar Pharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$719.89M1.44$98.09M$2.0311.50
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Amphastar Pharmaceuticals has a net margin of 13.63% compared to Neoleukin Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 17.58% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals13.63% 17.58% 8.27%
Neoleukin Therapeutics N/A -37.22%-30.91%

Amphastar Pharmaceuticals currently has a consensus price target of $27.43, suggesting a potential upside of 17.47%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.11
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Amphastar Pharmaceuticals beats Neoleukin Therapeutics on 14 of the 15 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NLTX vs. The Competition

Export
MetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$252.34M$886.50M$6.24B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio-8.631.7129.0628.45
Price / SalesN/A119.94475.4361.47
Price / CashN/A20.0727.6236.52
Price / Book2.427.599.696.64
Net Income-$57.56M-$4.80M$3.55B$332.53M
7 Day Performance-0.67%-0.16%1.46%1.83%
1 Month Performance29.77%5.40%5.35%8.98%
1 Year Performance58.22%30.99%33.88%39.30%

Neoleukin Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NLTX
Neoleukin Therapeutics
N/A$26.85
+2.9%		N/AN/A$252.34MN/AN/A90
AKTS
Aktis Oncology
1.7687 of 5 stars		$18.72
+0.6%		$32.00
+70.9%		N/A$999.70M$6.50MN/A76
ALVO
Alvotech
3.847 of 5 stars		$3.30
-6.3%		$7.60
+130.3%		N/A$995.97M$588.90M33.001,460
SVRA
Savara
1.7187 of 5 stars		$4.85
-3.4%		$9.13
+88.1%		N/A$993.87MN/AN/A20
CRON
Cronos Group
1.0128 of 5 stars		$2.58
-2.6%		$2.30
-10.9%		N/A$970.78M$146.59MN/A450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel